SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

14 Feb 2023 Evaluate
The sales is pegged at Rs. 3441.25 millions for the December 2022 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 4430.01 millions during the year-ago period.The Net Loss for the quarter ended December 2022 is Rs. -92.89 millions as compared to Net Profit of Rs. 97.32 millions of corresponding quarter ended December 2021Operating profit for the quarter ended December 2022 decreased to 146.85 millions as compared to 471.19 millions of corresponding quarter ended December 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 3441.25 4430.01 -22.32 11357.95 11920.23 -4.72 16682.56 15428.96 8.12
Other Income 132.40 5.30 2398.11 243.14 107.73 125.69 112.93 27.22 314.88
PBIDT 146.85 471.19 -68.83 602.04 1204.61 -50.02 1701.31 1129.49 50.63
Interest 174.64 176.24 -0.91 598.18 613.78 -2.54 788.10 1120.32 -29.65
PBDT -27.79 294.95 -109.42 3.86 590.83 -99.35 913.21 -243.98 -474.30
Depreciation 147.84 142.78 3.54 442.70 427.10 3.65 569.68 602.53 -5.45
PBT -175.63 152.17 -215.42 -438.84 163.73 -368.03 343.53 -846.51 -140.58
TAX -82.74 54.85 -250.85 -160.63 27.10 -692.73 90.34 -115.04 -178.53
Deferred Tax -82.74 54.85 -250.85 -160.63 27.10 -692.73 90.34 -200.90 -144.97
PAT -92.89 97.32 -195.45 -278.21 136.63 -303.62 253.19 -731.47 -134.61
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 3.80 9.18 -58.67 5.30 10.11 -47.55 8.84 6.41 37.98

Nectar Lifesciences Share Price

12.26 0.32 (2.68%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×